NCT05740150

Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients.

The Efficacy of a Lock Solution Containing Taurolidine, Citrate and Heparin for the Prevention of Tunneled Central Line-associated Bloodstream Infections in Pediatric Oncology Patients, a Randomized Controlled, Mono-center Trial.

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 462 (estimated)
• Sponsor: Princess Maxima Center for Pediatric Oncology · Academic / Other
• Sex: All
• Age: 0 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this assessor blinded randomized controlled trial is to compare a lock solution containing taurolidine, citrate and heparin to a heparin only lock solution for the prevention of central line associated bloodstream infections in paediatric oncology patients with a central venous access device.

Conditions

• Central Line-associated Bloodstream Infection (CLABSI)

Interventions

Type	Name	Description
DEVICE	TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)	The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
DEVICE	Heparin lock (heparin 100 IU/mL)	The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.

Timeline

• Start date: 2020-10-27
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2023-02-22
• Last updated: 2023-02-22

Locations

1 site across 1 country: Netherlands